Mark T. Bilodeau

Medicine · Health Sciences

36h-index5.8kcitations126works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Research Studies(22), Neuroendocrine Tumor Research Advances(21), Heat shock proteins research(15), Cancer therapeutics and mechanisms(15), HER2/EGFR in Cancer Research(11)

Publications126 total

Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Data from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplementary Figure 4 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Data from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplementary Figure 3 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplementary Synthesis Route from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplemental Figure S4 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplementary Synthesis Route from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplementary Figure S1 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplementary Figure 3 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplemental Materials and Methods from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplemental Figure S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplementary figure 2 from Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors
2023Open Access
Supplemental Table S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
Data from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
2023Open Access
page 1 of 7Next →

Frequent Co-authors

George D. Hartman(23), Scott D. Kuduk(10), Christina N. Di Marco(9), Ronald K. Chang(8), Peter J. Manley(7), William J. Ray(7), Lei Ma(7), Marion Wittmann(7), Matthew A. Seager(7), Charles D. Thompson(7), Keith Rickert(7), David A. Evans(6), Kathleen Coll(6), Kenneth A. Thomas(6), Michael Leitl(6), Stanley F. Barnett(5), Deborah Defeo-Jones(5), R. Robinson(5), Hans E. Huber(5), Kenneth A. Koeplinger(5)